Listed by the USPTO as MYERS, CARLA J
Tech Center 1600 • Art Units: 1600 1613 1634 1671 1678 1682
This examiner grants 50% of resolved cases
MYERS, CARLA J is assigned to Tech Center 1600 and art unit 1600. The profile covers 1041 resolved cases and shows a 49.5% allowance rate. Median time to allowance is 1139 days. Interviews are associated with a 46.0% lift in the reported allowance outcome.
The leading companies are Illumina Inc., The Children's Hospital of Philadelphia, and BIOASTER. The principal firms are HOWSON & HOWSON LLP, OLIFF PLC, and Casimir Jones, S.C. The recorded allowance rate and duration support careful portfolio scheduling, while the interview figure supports using examiner discussions as part of a focused response plan.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19397515 | UNIVERSAL EARLY CANCER DIAGNOSTICS | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18606690 | METHODS, COMPOSITIONS, AND SYSTEMS FOR CAPTURING PROBES AND/OR BARCODES | Non-Final OA | 10x Genomics, Inc. |
| 18717006 | SINGLE-CELL CULTURE AND SEQUENCING WITH LIPID-MODIFIED OLIGOS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17653114 | Systems and Methods to Identify Pancreatic Ductal Adenocarcinoma and Uses Thereof | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17637410 | BLOOD GENE BIOMARKERS TO DIAGNOSE AND PREDICT ACUTE REJECTION IN LIVER TRANSPLANT RECIPIENTS | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 18540667 | METHODS AND COMPUTER PRODUCTS FOR MEASURING THE AMOUNT OF CELLS OF A PARTICULAR CELL LINEAGE | Non-Final OA | The Chinese University of Hong Kong |
| 18265029 | A METHOD FOR CLASSIFYING THE GUT INFLAMMATION STATUS IN AVIAN SPECIES | Final Rejection | Evonik Operations GmbH |
| 17429281 | ISOLATION AND DETECTION OF EXOSOME-ASSOCIATED MICROBIOME FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES | Non-Final OA | Board of Regents, The University of Texas System |
| 18607269 | METHODS OF TREATING PANCREATIC CANCER | Non-Final OA | University of Washington |
| 18290138 | CD274 MUTATIONS FOR CANCER TREATMENT | Non-Final OA | Foundation Medicine, Inc. |
| 18420482 | INFERRING MICROORGANISM OF ORIGIN FOR ANTIMICROBIAL RESISTANCE MARKERS IN TARGETED METAGENOMICS | Non-Final OA | Illumina, Inc. |
| 17026069 | METHODS AND COMPOSITIONS FOR IDENTIFYING LIGANDS ON ARRAYS USING INDEXES AND BARCODES | Non-Final OA | ILLUMINA, INC. |
| 18705818 | BIOMARKERS AND USES THEREFOR | Non-Final OA | GenoDx Pty Ltd |
| 18014814 | METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT | Non-Final OA | BIOASTER |
| 18014801 | METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT | Non-Final OA | BIOASTER |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy49.5% of resolved applications examined by Carla J Myers were allowed (1,041 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +46.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Carla J Myers took 1,139 days on average from filing to allowance.
Carla J Myers examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
